Amazons Top Health Executive Lindsay Steps Down Amwell Cofounder Dr Roy Schoenberg to Take Over SP 500 and Nasdaq Hold Steady as Investors Watch for Middle East Peace Developments Healthcare and Tech Lead SP 500 to Modest Gains Communication Services Lags Paul Tudor Jones Says Kevin Warsh No Chance to Influence Fed Rate Cuts Standard Chartered Plans to Cut Over 15 of Corporate Functions Roles Targets Higher Income per Employee New York Fed Study Reveals Surging Gas Prices Disproportionately Burden LowerIncome Consumers MCO Q1 2026 Earnings EPS Surpasses Estimates Despite Modest Stock Decline Metalla Royalty Streaming Q1 2026 Earnings EPS Misses Estimates but Stock Rises 545 on Strategic Progress Coherent Corp Q1 2026 Earnings EPS Slightly Misses Consensus Stock Edges Up TOI Q1 2026 Earnings Narrower Than Expected EPS Loss Drives Positive Market Reaction Super League Enterprise Inc SLE Q1 2026 Earnings NarrowerThanExpected Loss Amidst Stock Decline AUBN Q1 2026 Earnings Solid EPS of 063 Amid Stable Regional Bank Operations OFS Capital Corporation OFS Edges Higher Testing Resistance at 360 AEXA SPAC Stock Edges Lower as Trading Remains RangeBound Offerpad Solutions OPAD Rallies 77 to 075 Testing Key Resistance Near 079 NanoViricides NNVC Surges 159 as Speculative Buying Drives Shares Above 175 NCR Voyix VYX Gains 24 as Shares Test Key Levels US Consumer Prices Rise 38 in April Exceeding Expectations Heidmar Maritime Holdings Corp HMR Q4 2025 Earnings Significant EPS Miss Amidst Operational Headwinds 1stdibscom Inc DIBS Tests Support Zone After Recent Uptick Acumen Pharmaceuticals ABOS Gains Nearly 5 as Stock Tests Resistance at 267 Oxford Lane Capital 2029 Preferred Shares OXLCO Hold Steady as FixedIncome Market Finds Footing Ascentage Pharma AAPG Advances 22 as Biotech Sector Finds Footing ProQR Therapeutics PRQR Soars 83 Analyzing the Rally and Key Levels to Watch Propanc Biopharma PPCB Slides 69 as Weak Momentum Tests Key Support Hilton Grand Vacations HGV Slips 114 as Stock Tests Key Support Levels NewAmsterdam Pharma Warrant NAMSW Faces Sharp Decline Testing Key Support